A recent post hoc analysis assesses whether PSA changes can predict survival outcomes in patients with metastatic or very high risk nonmetastatic prostate cancer.
This article was reviewed by Darragh O’Carroll, MD. Prostate-specific antigen (PSA) is a term you’ll probably become familiar with once you start getting screened regularly for prostate cancer ...
Prostate-specific antigen (PSA) blood testing likely reduces the risk of death from prostate cancer, found a new review ...
A new blood test could help doctors identify whether a treatment for advanced prostate cancer is failing weeks earlier than ...
In a population-based cohort study, a single prostate-specific antigen (PSA) measurement in men aged 45-70 years effectively identified individuals with low risk for cancer. Men with PSA levels < 1.00 ...
Forbes contributors publish independent expert analyses and insights. Joshua Cohen is a Boston-based writer who covers health policy. This voice experience is generated by AI. Learn more. This voice ...
Health-evidence reviewers reverse recommendation on a blood test that detects a biomarker of a common cancer after decades of ...
Novartis today announced new data from PSMAddition demonstrating improved prostate-specific antigen (PSA) responses with ...
If it wasn’t for a chance encounter at a coffee shop in Almonte 25 years ago, Terry Cairns thinks he wouldn’t be alive today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results